Cisatracurium besylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 310148

CAS#: 96946-42-8 (besylate)

Description: Cisatracurium (formerly recognized as 51W89, and marketed as Nimbex) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture.

Chemical Structure

Cisatracurium besylate
CAS# 96946-42-8 (besylate)

Theoretical Analysis

MedKoo Cat#: 310148
Name: Cisatracurium besylate
CAS#: 96946-42-8 (besylate)
Chemical Formula: C65H82N2O18S2
Exact Mass: 1242.50041
Molecular Weight: 1243.48
Elemental Analysis: C, 62.78; H, 6.65; N, 2.25; O, 23.16; S, 5.16

Price and Availability

Size Price Availability Quantity
25.0mg USD 350.0 2 Weeks
50.0mg USD 650.0 2 Weeks
100.0mg USD 950.0 2 Weeks
Bulk inquiry

Related CAS #: Cisatracurium (free base)   96946-42-8 (besylate)  

Synonym: (1R1R2R2R)2215Pentanediylbisoxy(3oxo31propanediyl)bis1(34dimethoxyphenyl)methyl1234tetrahydro67dimethoxy2methylisoquinolinium dibenzenesulfonate; Cisatracurium besilat

IUPAC/Chemical Name: (1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfonate


InChi Code: InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2/t42-,43-,54-,55-;;/m1../s1

SMILES Code: O=C(OCCCCCOC(CC[N@+]1(C)[C@H](CC2=CC=C(OC)C(OC)=C2)C3=C(C=C(OC)C(OC)=C3)CC1)=O)CC[N@+]4(C)[C@H](CC5=CC=C(OC)C(OC)=C5)C6=C(C=C(OC)C(OC)=C6)CC4.O=S(C7=CC=CC=C7)([O-])=O.O=S(C8=CC=CC=C8)([O-])=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1243.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Zuo M, Gao J, Zhang X, Cui Y, Fan Z, Ding M. Capillary electrophoresis with electrochemiluminescence detection for the simultaneous determination of cisatracurium besylate and its degradation products in pharmaceutical preparations. J Sep Sci. 2015 Jul;38(13):2332-9. doi: 10.1002/jssc.201500092. Epub 2015 May 13. PubMed PMID: 25872750.

2: Geng Z, Wu X. [Neuromuscular effects of cisatracurium besylate in obese patients]. Zhonghua Yi Xue Za Zhi. 2014 Sep 30;94(36):2844-6. Chinese. PubMed PMID: 25534104.

3: Dahaba AA, Suljevic I, Oettl K, Xiao Z, Dong H, Xiong L, Reibnegger G. Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. Minerva Anestesiol. 2013 Nov;79(11):1238-47. Epub 2013 May 23. PubMed PMID: 23698546.

4: Dahaba AA, Wang G, Xu X, Liu X, Wu X, Bornemann H, Metzler H. Influence of acute normovolaemic haemodilution on the dose-response relationship and time course of action of cisatracurium besylate. Br J Anaesth. 2007 Mar;98(3):342-6. Epub 2007 Jan 16. PubMed PMID: 17227819.

5: Imbeault K, Withington DE, Varin F. Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. Anesth Analg. 2006 Mar;102(3):738-43. PubMed PMID: 16492821.

6: de Ruiter J, Crawford MW. Dose-response relationship and infusion requirement of cisatracurium besylate in infants and children during nitrous oxide-narcotic anesthesia. Anesthesiology. 2001 May;94(5):790-2. PubMed PMID: 11388529.

7: Xu QA, Zhang YP, Trissel LA, Gilbert DL, Martinez JF, Fox JL. Stability of cisatracurium besylate in vials, syringes, and infusion admixtures. Am J Health Syst Pharm. 1998 May 15;55(10):1037-41. PubMed PMID: 9606456.

8: Zhang H, Wang P, Bartlett MG, Stewart JT. HPLC determination of cisatracurium besylate and propofol mixtures with LC-MS identification of degradation products. J Pharm Biomed Anal. 1998 Mar;16(7):1241-9. PubMed PMID: 9571542.

9: Jensen FS, Mogensen JV. [Cisatracurium besylate--Nimbex]. Ugeskr Laeger. 1998 Feb 2;160(6):858-60. Danish. PubMed PMID: 9469987.

10: Trissel LA, Martinez JF, Gilbert DL Jr. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health Syst Pharm. 1997 Aug 1;54(15):1735-41. PubMed PMID: 9262747.